struggle to get access to<unk> in the 2013-2016 Ebola epidemic was primarily socio-economic, not technical<unk> development and production is<unk> lly complex and prone to market failure. Many of the diseases most demanding a<unk>  including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop<unk>  for these diseases because there is little revenue potential. Even in more affluent countries, financial returns are usually minimal and the financial and other risks are great. Most<unk> development to date has relied on "push" funding by government, universities and non-profit organizations. Many<unk>  have been highly cost effective and beneficial for public health. The number of<unk>  actually administered has risen dramatically in recent decades. This increase, particularly in the number of different<unk>  administered to children before entry into schools may be due to government mandates and support, rather than<unk> incentive.
Economics of vaccines
Vaccination policy
Timeline of human vaccines
Public health surveillance
Bacterial phylodynamics
HIV/AIDS research
Outline of public health
VIOLIN vaccine database